Myeloma
Myeloma
The latest news, research, and perspectives in multiple myeloma. Multiple myeloma is characterized by the proliferation of malignant plasma cells that accumulate in the bone marrow and produce abnormal immunoglobulin. Read more about the pathophysiology, diagnosis, staging, and treatment of myeloma.
Advertisement
James Berenson, MDVideo Insights | July 12, 2024
James Berenson, MD, of the Berenson Cancer Center, discusses the launch of the Myeloma BioBank.
View More
Salomon Manier, MD, PhDMyeloma | July 1, 2024
Dr. Manier tells of which new phase III data he finds especially exciting in myeloma care.
Ola Landgren, MD, PhDMyeloma | June 17, 2024
Ola Landgren, MD, PhD, discusses three studies on quadruplet therapy presented at the 2024 ASCO Annual Meeting.
Luciano Costa, MDMyeloma | June 3, 2024
Dr. Costa presents subgroup findings from the single-line therapy patients in the CARTITUDE-4 phase III trial.
Blood Cancer TalksMyeloma | May 30, 2024
Drs. Hira Mian and Manni Mohyuddin join the hosts of "Blood Cancer Talks" for an overview of myeloma maintenance therapy.
Patrick DalyMyeloma | May 21, 2024
Cilta-cel is now indicated for adult patients who have received at least one prior line of therapy.
Advertisement
Donna Catamero, ANP-BC, OCN, CCRCMyeloma | May 21, 2024
Donna Catamero, ANP-BC, OCN, CCRC, discusses selinexor for myeloma, the BOSTON trial, and other recent advances in myeloma.
Patrick DalyMyeloma | April 19, 2024
The FDA ODAC voted in favor of the use of MRD-negativity as an intermediate endpoint for accelerated approval in MM trials.
Kenneth Anderson, MDMyeloma | April 11, 2024
The “real revolution” in myeloma is in the immune therapies, Dr. Anderson said, such as bispecific T-cell engagers and ...
Melissa BadamoMyeloma | April 8, 2024
The overall response rate was 71%, and the most common side effects were CRS, neutropenia, and anemia.
Leah SherwoodMyeloma | May 21, 2024
Cilta-cel was previously approved by the FDA in relapsed or refractory MM after four or more prior lines of therapy.
Patrick DalyMyeloma | May 21, 2024
The expansion of the indication was supported by positive data from the KarMMa-3 study.
Blood Cancer TalksMyeloma | March 29, 2024
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Melissa BadamoMyeloma | April 23, 2024
The approval was based on results from the KarMMa-3 study, which compared ide-cel with standard combination regimens.
Blood Cancers Today Staff WritersMyeloma | March 18, 2024
The 11-member panel of independent experts voted eight in favor and three against.
Blood Cancers Today Staff WritersMyeloma | March 15, 2024
The FDA Oncologic Drugs Advisory Committee voted to recommend approval of the supplemental BLA for cilta-cel in myeloma.
Melissa BadamoMyeloma | March 13, 2024
For Dr. Banerjee, this month is a call to action to mitigate global disparities in myeloma treatment.
Melissa BadamoMyeloma | March 12, 2024
S. Vincent Rajkumar, MD, a myeloma clinician and researcher, currently serves as a Professor of Medicine at the Mayo Clinic.
Melissa BadamoMyeloma | March 8, 2024
Sebia’s free light chain (FLC) kappa and lambda assays have 510(k) clearance.
Patrick DalyMyeloma | March 19, 2024
A phase I clinical trial on IDP-023 is currently enrolling patients.
Advertisement
Advertisement
Editorial Board